Holen Sie sich die Stockscreener-App
2.83
2.54%
0.07
Handel nachbörslich:
2.83
Schlusskurs vom Vortag:
$2.76
Offen:
$2.75
24-Stunden-Volumen:
732.00K
Relative Volume:
1.49
Marktkapitalisierung:
$66.82M
Einnahmen:
$156.31M
Nettoeinkommen (Verlust:
$-245.76M
KGV:
-3.3294
EPS:
-0.85
Netto-Cashflow:
$-234.16M
1W Leistung:
-7.21%
1M Leistung:
+5.99%
6M Leistung:
-79.15%
1J Leistung:
-81.21%
1-Tages-Spanne:
$2.66
$2.91
1-Wochen-Bereich:
$2.65
$3.045
52-Wochen-Spanne:
$2.50
$19.69
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Vergleichen Sie AGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
2.83 | 66.82M | 156.31M | -245.76M | -234.16M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Agenus (AGEN) Stock Surges Amid Positive Market Movement - GuruFocus.com
Agenus to Present Groundbreaking Colorectal Cancer Treatment Data at ASCO GI Symposium - StockTitan
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
Agenus (AGEN) Stock Plummets 5.08% Amidst Mixed Ratings - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Agenus Inc. Class Action: The Gross Law Firm Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024AGEN - Kilgore News Herald
Agenus Inc. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm for More InformationAGEN - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class ActionContact The Gross Law Firm to Learn More - Victoria Advocate
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus - BioSpace
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming DeadlinesAGEN - The Eastern Progress Online
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - The Eastern Progress Online
Shareholders that lost money on Agenus Inc.(AGEN) should contact The Gross Law Firm about pending Class Action - Longview News-Journal
HC Wainwright Has Optimistic Outlook of Agenus Q4 Earnings - MarketBeat
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
Q1 Earnings Forecast for Agenus Issued By HC Wainwright - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus - The Eastern Progress Online
Walleye Capital LLC Acquires New Holdings in Agenus Inc. (NASDAQ:AGEN) - MarketBeat
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B - BioPharma Dive
Agenus Restructures to Cut Costs 60%, Doubles Down on Promising Cancer Drug Program - StockTitan
Agenus (AGEN) Q3 2024 Earnings Call Transcript - AOL
Agenus (AGEN) Stock Drops 5.50% Amid Biotech Sector Decline - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Short Interest Update - MarketBeat
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
H.C. Wainwright reiterates Neutral on Agenus stock, focus on bot/bal in colorectal cancer - Investing.com India
HC Wainwright Reaffirms "Neutral" Rating for Agenus (NASDAQ:AGEN) - MarketBeat
Agenus secures $22 million mortgage, plans cost cuts By Investing.com - Investing.com Canada
Agenus secures $22 million mortgage, plans cost cuts - Investing.com India
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development - Yahoo Finance
Agenus Secures $22M Mortgage to Advance Cancer Treatment - TipRanks
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
Shareholders that lost money on Agenus Inc.(AGEN) should contact - GuruFocus.com
Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - GuruFocus.com
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
What is B. Riley's Forecast for Agenus FY2024 Earnings? - MarketBeat
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Agenus stock hits 52-week low at $2.56 amid market challenges - Investing.com Australia
Agenus Chooses Flex Databases for Enhanced Pharmacovigilance Solutions - openPR
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
William Blair Weighs in on Agenus' Q4 Earnings (NASDAQ:AGEN) - MarketBeat
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround - Yahoo Finance
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):